Terms: = Skin cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
41 results:
1. Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.
Zago E; Galluzzo A; Pradella S; Antonuzzo L; Maggi M; Petrone L; Sparano C
Endocrine; 2024 Jan; 83(1):26-40. PubMed ID: 37851242
[TBL] [Abstract] [Full Text] [Related]
2. Urine-derived exosomes from individuals with IPF carry pro-fibrotic cargo.
Elliot S; Catanuto P; Pereira-Simon S; Xia X; Shahzeidi S; Roberts E; Ludlow J; Hamdan S; Daunert S; Parra J; Stone R; Pastar I; Tomic-Canic M; Glassberg MK
Elife; 2022 Dec; 11():. PubMed ID: 36454035
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical and genetic analysis of seven Chinese pedigrees affected with multiple endocrine neoplasia type 2A with cutaneous lichen amyloidosis].
Fang X; Wang H; Dong F; Lian B; Li F; Jin H; Yu Y; Zhang N; Qi X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2022 Sep; 39(9):938-943. PubMed ID: 36082561
[TBL] [Abstract] [Full Text] [Related]
4. trk Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.
Ernst MS; Lysack JT; Hyrcza MD; Chandarana SP; Hao D
Curr Oncol; 2022 May; 29(6):3933-3939. PubMed ID: 35735423
[TBL] [Abstract] [Full Text] [Related]
5. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (trka) Inhibitors: Synthesis, Anticancer Activities,
Alam MS; Lee DU
Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310
[TBL] [Abstract] [Full Text] [Related]
6. Factors associated with melanoma-related limb lymphoedema.
Gjorup CA; Dahlstroem K; Hendel HW; Drzewiecki KT; Klausen TW; Hölmich LR
Acta Oncol; 2021 Jun; 60(6):779-784. PubMed ID: 33793386
[TBL] [Abstract] [Full Text] [Related]
7. Multidisciplinary treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 trkaIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A.
Guadagni S; Farina AR; Cappabianca LA; Sebastiano M; Maccarone R; Zelli V; Clementi M; Chiominto A; Bruera G; Ricevuto E; Fiorentini G; Sarti D; Mackay AR
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153070
[TBL] [Abstract] [Full Text] [Related]
8. Vandetanib for the Management of Advanced Medullary Thyroid cancer: A Real-World Multicenter Experience.
Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
[TBL] [Abstract] [Full Text] [Related]
9. Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Ramos HE; Hecht F; Berdelou A; Borget I; Leboulleux S; Baudin E; Schlumberger M
Endocrine; 2021 Feb; 71(2):434-442. PubMed ID: 32691271
[TBL] [Abstract] [Full Text] [Related]
10. Ntrk gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
Forschner A; Forchhammer S; Bonzheim I
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
[TBL] [Abstract] [Full Text] [Related]
11. A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.
Yin Y; Qiu XY; Zhang YH; Zhang B
Medicine (Baltimore); 2019 Aug; 98(31):e16392. PubMed ID: 31374006
[TBL] [Abstract] [Full Text] [Related]
12. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study].
Wang SX; Zhang XW; Wang XX; An CM; Zhang YB; Liu W; Zhao YF; He XH; Li ZJ; Niu LJ; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jun; 54(6):439-444. PubMed ID: 31262109
[No Abstract] [Full Text] [Related]
13. The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: A systematic review.
Rowell NP
Radiother Oncol; 2019 Jul; 136():113-120. PubMed ID: 31015112
[TBL] [Abstract] [Full Text] [Related]
14. Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Danilenko M; Stamp E; Stocken DD; Husain A; Zangarini M; Cranston A; Stones R; Sinclair N; Hodgson K; Bowett SA; Roblin D; Traversa S; Plummer R; Veal G; Langtry JAA; Ashworth A; Burn J; Rajan N
JAMA Dermatol; 2018 Aug; 154(8):913-921. PubMed ID: 29955768
[TBL] [Abstract] [Full Text] [Related]
15. The curious case of a forehead metatypical basal cell carcinoma.
Florescu IP; Turcu EG; Carantino AM; Cocoşilă LC; Enache V; Neagu TP; Jecan CR
Rom J Morphol Embryol; 2018; 59(1):345-352. PubMed ID: 29940648
[TBL] [Abstract] [Full Text] [Related]
16. Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.
Wehkamp U; Stern S; Krüger S; Weichenthal M; Hauschild A; Röcken C; Egberts F
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1301-1308. PubMed ID: 29744662
[TBL] [Abstract] [Full Text] [Related]
17. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Brose MS; Bible KC; Chow LQM; Gilbert J; Grande C; Worden F; Haddad R
Cancer Treat Rev; 2018 May; 66():64-73. PubMed ID: 29704768
[TBL] [Abstract] [Full Text] [Related]
18. ALK Inhibitor Response in Melanomas Expressing
Couts KL; Bemis J; Turner JA; Bagby SM; Murphy D; Christiansen J; Hintzsche JD; Le A; Pitts TM; Wells K; Applegate A; Amato C; Multani P; Chow-Maneval E; Tentler JJ; Shellman YG; Rioth MJ; Tan AC; Gonzalez R; Medina T; Doebele RC; Robinson WA
Mol Cancer Ther; 2018 Jan; 17(1):222-231. PubMed ID: 29054983
[TBL] [Abstract] [Full Text] [Related]
19. Sunitinib in the treatment of Thyroid cancer.
Ferrari SM; Centanni M; Virili C; Miccoli M; Ferrari P; Ruffilli I; Ragusa F; Antonelli A; Fallahi P
Curr Med Chem; 2019; 26(6):963-972. PubMed ID: 28990511
[TBL] [Abstract] [Full Text] [Related]
20. Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells.
Wehkamp U; Stern S; Krüger S; Hauschild A; Röcken C; Egberts F
JAMA Dermatol; 2017 Nov; 153(11):1166-1169. PubMed ID: 28793172
[TBL] [Abstract] [Full Text] [Related]
[Next]
